

Kidron Miriam  
Form 4  
November 23, 2012

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kidron Miriam

2. Issuer Name and Ticker or Trading Symbol  
ORAMED PHARMACEUTICALS INC. [ORMP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
08/14/2007

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Technology Officer

C/O ORAMED PHARMACEUTICALS INC., 2 ELZA STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

JERUSALEM, L3 93706

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

## Edgar Filing: Kidron Miriam - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title a Underlyi (Instr. 3)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date	Title	
Warrant (right to buy)	\$ 0.001	08/14/2007		A			3,361,360		08/14/2007 <sup>(1)</sup>	08/14/2012	Comm Stock	
Warrant (right to buy)	\$ 0.001	08/08/2012		D <sup>(2)</sup>			3,361,360		08/14/2007 <sup>(1)</sup>	08/14/2012	Comm Stock	
Warrant (right to buy)	\$ 0.001	08/08/2012		A <sup>(2)</sup>			3,361,360		08/08/2012 <sup>(1)</sup>	08/06/2014	Comm Stock	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kidron Miriam C/O ORAMED PHARMACEUTICALS INC. 2 ELZA STREET JERUSALEM, L3 93706	X		Chief Technology Officer	

## Signatures

/s/ Miriam  
Kidron

11/23/2012

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The warrant was fully vested on the date of issuance.

(2) The two reported transactions involved an amendment of an outstanding warrant to extend the expiration date to August 6, 2014, resulting in the deemed cancellation of the "old" warrant and the grant of a replacement warrant.

(3) The warrant was granted in recognition of Dr. Kidron's contributions to the Issuer in connection with the initial development of its current business.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.